Skip to main content

Myokarditis nach Krebstherapie mit Immun-Checkpoint-Inhibitoren: Was zeigt die kardiale MRT?

Myocarditis after cancer treatment with immune checkpoint inhibitors: what does cardiac MRI show?

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19:e447–e58

    CAS  Article  Google Scholar 

  2. 2.

    Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D et al (2020) Onkologische Kardiologie. Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie. Kardiologe 14:267–293

    Article  Google Scholar 

  3. 3.

    Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636–2648 (48a–48d)

    Article  Google Scholar 

  4. 4.

    Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158–3176

    Article  Google Scholar 

  5. 5.

    Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F et al (2020) Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41:1733–1743

    CAS  Article  Google Scholar 

  6. 6.

    Friedrich MG (2020) Immune checkpoint inhibitor cardiotoxicity: what can we learn from real life data on CMR as a diagnostic tool? Eur Heart J 41:1744–1746

    Article  Google Scholar 

  7. 7.

    Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 22:1504–1524

    CAS  Article  Google Scholar 

  8. 8.

    Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140:80–91

    Article  Google Scholar 

  9. 9.

    Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Florian von Knobelsdorff.

Ethics declarations

Interessenkonflikt

F. von Knobelsdorff gibt an, dass kein Interessenkonflikt besteht.

Additional information

figureqr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

von Knobelsdorff, F. Myokarditis nach Krebstherapie mit Immun-Checkpoint-Inhibitoren: Was zeigt die kardiale MRT?. Kardiologe 15, 423–426 (2021). https://doi.org/10.1007/s12181-021-00496-3

Download citation